← Leaderboards
Andrew Napper
Nemours Children'S Hospital, Delaware
$768,580
Attributed
$768,580
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $312.2K · FY2010–16$500K$375K$250K$125K$0
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$768,580 · 2
By mechanism
R01$607,955 · 1
R21$160,625 · 1
Top collaborators
No co-investigators on record.
Most similar at Nemours Children'S Hospital, Delaware
Same institution · by research overlap
- Edward Anders Kolb$7,151,439
Others in their field
Top investigators on “Leukemia”
- Richard K. Wilson · Washington University$209,620,938
- David Heimbrook · Leidos Biomedical Research, Inc.$168,419,678
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,967,203
- Peter C Adamson · National Childhood Cancer Foundation$143,910,899
- Ralph Parchment · Leidos Biomedical Research, Inc.$141,315,269
- Richard L Schilsky · University Of Chicago$129,102,207
Research focus
LeukemiaInhibitor/AntagonistDetectionLeadHistonesHoxa9 GeneChildCounterscreenGenesGene ExpressionHigh Throughput ScreeningHistone MethyltransferaseBaseBlood CellsCell LineCellsChildhood LeukemiaChimeric ProteinsDoseDisease-Free SurvivalDrug CandidateEmployee StrikesBiochemicalLeukemogenesis
Grant awards (4)
Assay Development for NSD1 Methyltransferase Inhibitor Discovery$312,244
R01 · FY2016 · CA · contact PI
Assay Development for NSD1 Methyltransferase Inhibitor Discovery$295,711
R01 · FY2015 · CA · contact PI
Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia$33,125
R21 · FY2012 · NS · contact PI
Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia$127,500
R21 · FY2010 · NS · contact PI